Neisvac-C

Neisseria meningitidis group C polysaccharide (de-O-acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac‑C, is a vaccine presented as a vaccine formulation for intramuscular use. It induces immunity to prevent invasive meningococcal disease caused by serogroup C in children, adolescents and adults, including high‑risk populations such as travelers to endemic regions.

GNH USA supplies Neisvac‑C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Neisvac‑C is a conjugate meningococcal vaccine that targets the polysaccharide capsule of Neisseria meningitidis serogroup C. - Prevention of invasive meningococcal disease caused by serogroup C: provides active immunity to reduce incidence of meningitis, septicemia and related complications. - Outbreak control in community settings: contributes to herd immunity and helps limit spread during serogroup C outbreaks. - Travel protection for individuals visiting endemic areas: offers prophylactic coverage against serogroup C exposure.

Neisvac‑C, like other conjugate vaccines, may be associated with local and systemic reactions after injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: transient erythema or edema around the site. - Fever: low‑grade temperature elevation within 24‑48 hours. - Headache: mild headache commonly reported. - Fatigue: temporary tiredness following immunisation. - Myalgia: muscle aches may occur.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare immune‑mediated neuropathy. - Seizure: infrequent neurologic event. - Hypotension: sudden drop in blood pressure. - Immune‑mediated thrombocytopenia: low platelet count. - Severe allergic reaction: includes angioedema or respiratory distress.

Before administering Neisvac‑C, healthcare professionals should consider the following precautions. - Pregnancy: safety has not been established; vaccinate only if benefit outweighs potential risk. - Breastfeeding: weigh potential benefits for the infant against unknown risks. - Immunocompromised patients: vaccine may elicit a reduced immune response. - History of severe allergic reaction to any component of the vaccine: contraindicates use. - Concurrent administration with other vaccines: generally permissible but monitor for additive reactogenicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac‑C may interact with other medicines or biologics as follows.

Major Interactions (Avoid): - Concurrent administration of immunoglobulin or blood products within 4 weeks: may diminish vaccine‑induced immunity. - Live bacterial vaccines (e.g., BCG) given within 4 weeks before or after: may interfere with immune response.

Moderate Interactions (Monitor Closely): - Use of antipyretics (acetaminophen, ibuprofen) around vaccination: may mask fever but generally safe. - Immunosuppressive therapy (corticosteroids, chemotherapy): may reduce antibody production. - Pregnancy‑related hormonal changes: could modify immune response, monitor effectiveness.